Bird & Bird, Life Sciences | Chambers Europe Profile

About

Provided by Bird & Bird

Our International Life Sciences & Healthcare group works with over 50% of the world’s largest pharmaceutical, biotechnology and medical devices companies. We have the largest patent litigation group in Europe and are recognised by major global directories as a top tier life sciences firm. With increased regulatory scrutiny, pricing and cost pressures, as well as the rapid developments in genomic technology leading to a more personalised approach to medicine and healthcare, businesses and organisations in the life sciences and healthcare sector face a growing number of complex legal and regulatory challenges in order to stay competitive. Our focus on business being changed by technology and the digital world enables us to support our clients operating in this rapidly changing environment. Our multidisciplinary team of 280 specialist life sciences and healthcare lawyers worldwide can advise you on every aspect of the business cycle of a life science and healthcare product or service, from incorporation through development to protection and exploitation of intellectual property.

Chambers Review

Provided by Chambers

Life Sciences - Europe-wide

Band 2

What the team is known for

Bird & Bird has an impressive team with notable offices in the UK, Italy and Spain, and additional branches in Germany and Belgium. The law firm has particular strength in IP mandates, advising on patent revocation and litigation. It is also active on corporate mandates, advising clients on cross-border acquisitions and collaboration agreements. Bird & Bird further acts on regulatory aspects, including data protection and regulatory issues in clinical trials.

Notable practitioners

Key contacts at the firm are the co-heads of the international life sciences and healthcare group, Mark Hilton, in London, and Marc Martens, based in Brussels.

View ranking table

Work Highlights

Provided by Bird & Bird

Bird & Bird advised Teva on defending the grant of a Belgian medicinal product marketing authorisation, which is being challenged in the Belgian courts.